Gegen Menschliches Hmgi-C-Antigen Spezifische Antikörper und Verwendung davon
Anmelder: PeriCard Check GmbH 🇩🇪
Details
- Veröffentlichungs-Nr.
- EP4640704
- Aktenzeichen
- EP24172812
- Anmeldetag
- 26. April 2024
- Veröffentlichung
- 29. Oktober 2025
- Rechtsraum
- EP
- IPC
- C07K16/24
Abstract
The disclosure relates to an (isolated) antibody (or antibody fragment/antigen binding fragment thereof) binding to (human) HMGI-C (anti-HMGI-C-Antibody) as well the nucleic acid encoding such an antibody or host cells comprising these or pharmaceutical composition comprising the antibody. Preferred antibodies are binding to the epitopes of SEQ. ID NOs. 32, 33 or 34, especially the (monoclonal) antibodies that comprise in its heavy chain variable region (VH) the amino acid CDR sequence CDR3 of SEQ ID NO. 4; in its heavy chain variable region (VH) the amino acid CDR sequence CDR3 of SEQ ID NO. 14; or in its heavy chain variable region (VH) the amino acid CDR sequence CDR3 of SEQ ID NO. 24. Especially preferred are also the (monoclonal) antibodies that comprise a heavy chain variable region (VH) having amino acid sequence of SEQ ID NO. 1 and a light chain variable region (VL) having amino acid sequence of SEQ ID NO. 6; that comprise a heavy chain variable region (VH) having amino acid sequence of SEQ ID NO. 11 and a light chain variable region (VL) having amino acid sequence of SEQ ID NO. 16; that comprise a heavy chain variable region (VH) having amino acid sequence of SEQ ID NO. 21 and a light chain variable region (VL) having amino acid sequence of SEQ ID NO. 26. In addition, the disclosure relates to a lateral flow device for the detection of HMGI-C, especially the HMGI-C released during an event leading to an acute aortic syndrome/acute aortic dissection (AAS/AAD) or in relation to cancer in a sample of bodily fluid of a human/patient using an antibody of the disclosure or to the use of the antibody for the treatment of cancer or for cancer prevention by early detection of HMGI-C as a marker for cancer.
Anmelder
- Firma
- PeriCard Check GmbH
- Land
- 🇩🇪 Deutschland
Fachgebiete
Münchner Patentanwaltskanzlei Dehmel & Bettenhausen, laut JUVE-Handbuch führend im Bereich Biotechnologie und Pharma. Berät zu Patenten, Gebrauchsmustern, Design, Marken, Arbeitnehmererfindungen und Sortenschutzrecht.